MedPath

Post Market Clinical Follow-up Study on da Vinci® Robotic-assisted Prophylactic Nipple Sparing Mastectomy With Breast Reconstruction

Terminated
Conditions
Prophylactic Nipple Sparing Mastectomy (NSM)
Interventions
Procedure: Nipple-Sparing Mastectomy
Registration Number
NCT05251285
Lead Sponsor
Intuitive Surgical
Brief Summary

The objective of this study is to collect post-market clinical safety and performance data on the robotic assisted prophylactic Nipple Sparing Mastectomy (R-NSM) surgery performed with the da Vinci Xi/X Surgical System as part of a PMCF Plan.

Detailed Description

This is an observational post-market study. Women will be screened for participation where the decision to undergo prophylactic R-NSM surgery has already been made as part of their medical care. In order for women to be enrolled, surgeons must perform the surgery according to the Instructions For Use (IFU) of da Vinci Xi/X Surgical System. Women will sign an informed consent form for their participation in the study. Women will be prospectively followed at 6 weeks, 3 months and 1 year post-surgery, which is within the standard of care. Data will be collected prospectively from the medical records and women will be asked to complete preoperative and postoperative questionnaires.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
7
Inclusion Criteria
  • Subject is a woman, candidate for a prophylactic R-NSM surgical procedure (unilateral or bilateral) according to the Instructions For Use (IFU) of da Vinci Xi/X Surgical System
  • Subject has cup size A, B or C,
  • Subject is 18 years of age or older,
  • Subject is a candidate for reconstruction,
  • Subject is willing to participate as demonstrated by signing the informed consent,
  • Subject benefits from a health care system/insurance.
Read More
Exclusion Criteria
  • Subject is pregnant or is lactating,
  • Subject has active cancer or pre-cancer (Ductal Carcinoma In Situ [DCIS]) on breast to be robotically operated,
  • Subject has cancer involving the Nipple Areolar Complex (NAC), inflammatory breast cancer or T4d lesion, clinical evidence of skin involvement or T4b lesion, and clinical or radiological evidence of chest wall invasion.
  • Subject has ASA score ˃ III or has known thromboembolism risks or, is at risk in relation to anesthesia,
  • Subject presents severe lack of cooperation due to psychological or severe systemic illness,
  • Subject has medical conditions contraindicating general anesthesia or surgical approach,
  • Subject is part of vulnerable population (e.g., prisoners, mentally disabled).
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Prophylactic Nipple-Sparing MastectomyNipple-Sparing Mastectomy-
Primary Outcome Measures
NameTimeMethod
Result of BREAST-QTM (Quality of life) at 3 months3 months after surgery
Result of BREAST-QTM (Quality of life) at 1 year1 year after surgery
OR & procedure (open surgery dissection, docking and console) times, including drainage and reconstruction timesAssessed during surgery to 6 weeks after surgery
Number of overall post-operative complications at 6 weeks6 weeks after the surgery
Number of overall post-operative complications at 3 months3 months after the surgery
Nipple-Areola Complex (NAC) Preservation Rate at 6 weeks after surgery6 weeks after surgery
Number of transfusion and transfused unitsAssessed during surgery to 6 weeks after surgery
Number of intraoperative R-NSM procedure and device-related complicationsAssessed during surgery to 42 days after surgery
Nipple-Areola Complex (NAC) necrosis occurrence (using SKIN composite score definition of D2 or higher) observed at 6 weeks after surgery6 weeks after surgery
Number of conversions to open surgeryAssessed during surgery
Number of readmissions associated with NSM surgery at 6 weeks6 weeks after surgery
Number of reoperations associated with NSM surgery at 6 weeks6 weeks after surgery
Number of overall post-operative complications at 1 year1 year after the surgery
Hospital Length of Stay (LOS)Assessed during the 6 weeks after surgery
Result of NAC questionnaire (Quality of life) at 1 year1 year after surgery
Results of the SKIN score (Mayo clinic) at 6 weeks or upon surgeon's practiceat 6 weeks or upon surgeon's practice
Number of readmissions associated with NSM surgery at 3 months3 months after surgery
Number of reoperations associated with NSM surgery at 3 months3 months after surgery
Result of NAC questionnaire (Quality of life) at 3 months3 months after surgery
Breast Cancer Occurrence Assessment at 1 year according to usual medical practice1 year after surgery
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Istituto Europeo di Oncologia

🇮🇹

Milan, Italy

Gustave Roussy Cancer Campus

🇫🇷

Villejuif, France

© Copyright 2025. All Rights Reserved by MedPath